Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Anemia and iron deficiency are common in older adults, yet their relevance to blood biomarkers for Alzheimer disease (AD) remains underappreciated. As these biomarkers move into clinical pathways, their interpretation depends not only on assay performance but also on comorbidity, kidney function, inflammation, and nutritional status. Against this backdrop, anemia, absolute iron deficiency, and functional iron deficiency are better viewed as distinct hematopoietic nutritional phenotypes than as background covariates, with important implications for interpreting the amyloid-β42/40 ratio, phosphorylated tau 217 (p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Current human data link anemia and iron-restricted states to higher dementia risk and to variation in plasma p-tau217, GFAP, and NfL; kidney function, body mass index (BMI), inflammation, and multimorbidity further shift biomarker distributions and cutoff interpretation. Among available analytes, p-tau217 is closest to routine clinical use within validated intended-use diagnostic pathways; however, its interpretation remains assay- and cutoff-specific and depends on pretest probability, gray-zone handling, kidney function, BMI, hemoglobin, ferritin, and transferrin saturation. Mechanistic work supports plausible links involving impaired oxygen delivery, disrupted iron-mitochondrial bioenergetics, hepcidin-mediated functional iron restriction, and glial, myelin, and blood-brain barrier vulnerability, although a complete human causal chain has not been established. Current evidence therefore favors phenotype-aware interpretation over hemoglobin-only screening or biomarker-only reading. In memory clinics and geriatric practice, complete blood count and iron studies may provide useful interpretive context in selected patients, particularly when multimorbidity, chronic kidney disease (CKD), inflammation, nutritional vulnerability, fatigue, or low or low-normal hemoglobin could affect biomarker interpretation or downstream decisions. Future studies should test whether, and in whom, correcting iron-related phenotypes changes biomarker-guided risk stratification, biomarker trajectories, or clinical decisions.

What this study adds

Evidence grade: Low

This review argues that anemia and iron deficiency are common conditions that can affect how Alzheimer's blood biomarkers such as p-tau217, GFAP and neurofilament light are interpreted, alongside kidney function, inflammation and body mass index. It notes that p-tau217 is closest to routine clinical use but that its interpretation depends on many patient factors, and that mechanistic work suggests plausible biological links between iron problems and brain health.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Li, Z., Ming, Q., Fu, L., Yang, J., Lv, Y., Chen, B., et al. (2026). Anemia, iron deficiency, and blood biomarkers for Alzheimer disease: clinical interpretation and dementia risk stratification. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2026.1897378

Vancouver

Li Z, Ming Q, Fu L, Yang J, Lv Y, Chen B, et al. Anemia, iron deficiency, and blood biomarkers for Alzheimer disease: clinical interpretation and dementia risk stratification. Frontiers in Nutrition. 2026. doi:10.3389/fnut.2026.1897378. PMID: 42534839.

BibTeX

@article{li2026-42534839,
  author  = {Li, Ze and Ming, Qiuli and Fu, Linpeng and Yang, Jingshuang and Lv, YiLin and Chen, BingQian and Qiu, Xiangjun and Lu, Zhaofeng},
  title   = {{Anemia, iron deficiency, and blood biomarkers for Alzheimer disease: clinical interpretation and dementia risk stratification}},
  journal = {Frontiers in Nutrition},
  year    = {2026},
  doi     = {10.3389/fnut.2026.1897378},
  pmid    = {42534839},
  url     = {https://doi.org/10.3389/fnut.2026.1897378}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review argues that anemia and iron deficiency are common conditions that can affect how Alzheimer's blood biomarkers such as p-tau217, GFAP and neurofilament light are interpreted, alongside kidney function, inflammation and body mass index. It notes that p-tau217 is closest to routine clinical use but that its interpretation depends on many patient factors, and that mechanistic work suggests plausible biological links between iron problems and brain health.

Study details

How this study scored 30/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 29 of the 96 points it could be judged on, which is 30 of 100. Total 30 of 100.29 of the 96 points we could judge = 30 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 29 of the 96 points we could judge it on, which is 30 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Nutrition)
Journal's citation record 1 / 4 Frontiers in Nutrition: journal h-index 147 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Zhaofeng Lu holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Henan University of Science and Technology: institution h-index 241 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42534839)
Free to read 2 / 2 Free to read
Points 29 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 96 points we could judge it on is 30 out of 100.
Total 30 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →